



Innovation: Changing the experience of serious illness

David Grainger

Senior Director, Global Public Policy

Eli Lilly and Company



Lilly

Acknowledgement


- A number of these slides have been provided by PhRMA, the US research-based industry association:

Pharmaceutical Research and Manufacturers of America®950 F Street, NW Suite 300,
Washington, DC 20004 - See more at:
<http://www.phrma.org/innovation/meds-in-development#sthash.yd3uB8vk.dpuf>

An innovation explosion

Immuno-therapies

Personalized medicine




Application of big data to R&D

Novel drug delivery mechanisms

More than 1,000 Medicines in Development for Various Cancers

*Number of Medicines in Development in the United States 2015, Selected Cancer Types**



“Scientifically, we have never been in a better position to advance cancer treatment. ... We now understand many of the cellular pathways that can lead to cancer. We have learned how to develop drugs that block these pathways.”


— Richard L. Schilsky, MD,
Professor, University of
Chicago

- Sources: Adis R&D Insight Database, 15 May 2015; American Society of Clinical Oncology, “Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention and Screening,” *Journal of Clinical Oncology*, 22 December 2008.

Five-Year Survival is Increasing for Many Types of Cancer

- The chances that a cancer patient will live 5 years or more has increased by 39% across cancers.

5-Year Survival Rates for Selected Cancers, 1975-2007




83% of survival gains in cancer are attributable to new treatments — including medicines.

- Sources: E. Sun, et al., "The Determinants of Recent Gains in Cancer Survival: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database," *Journal of Clinical Oncology*, May 2008 Suppl (Abstract 6616); American Cancer Society, "Cancer facts & Figures 2015," <http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf>; National Cancer Institute, Surveillance Epidemiology and End Results, Fast Stats: An interactive tool for access to SEER cancer statistics, <http://seer.cancer.gov/faststats>.

Personalized Medicine is Transforming Cancer Care

- **Biopharmaceutical companies focusing on personalized medicine has resulted in several recent approvals and a growing number of new medicines in the pipeline.**

12-50%



Of new drugs in the pipeline are reportedly personalized medicines (across all diseases)

73% of **cancer medicines** in the pipeline have the potential to be **personalized medicines**



“Oncology is on fire with [personalized medicine], with treatment selections based on individual molecular characteristics. This is also happening with chronic infectious diseases, and genetic diseases are not far behind.”


— Janet Woodcock, Director
Center for Drug Evaluation and
Research,
U.S Food and Drug Administration

- Sources: Tufts Center for the Study of Drug Development, “Impact Report,” Volume 17, No.3, May/June 2015; J.T. Aquino, “Personalized Medicine: Targeted Therapies Said Now Mainstream; Reimbursement, Clinical Trial Hurdles.” *Life Sciences Law and Industry Report*, 31 May 2013. Available at www.personalizedmedicinecoalition.org/sites/default/files/files/BloombergBNA.pdf.

The Role of Personalized Medicines Has Grown in the Last Decade

Personalized medicines provide effective and efficient care by targeting the right medicine to the right patient.

Oncology Treatment Modalities in Top Pharmaceutical Markets, 2003-2013




- Source: IMS Institute for Healthcare Informatics, "Innovation in Cancer Care and Implications for Health Systems: Global Oncology Trend Report," May 2014.

Changing the prognosis for malignant melanoma

- In 2010, ipilimumab became the first drug ever shown to extend survival for patients with metastatic melanoma in a large phase III trial. Ipilimumab reduced the risk of death by 32% and nearly doubled the likelihood of patients surviving to 1 and 2 years, with some patients experiencing complete and durable clinical regressions. Based on these results, ipilimumab was approved by the FDA as first-line therapy for advanced melanoma in 2011.
- The combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) has been tested in patients with advanced melanoma in several trials, with impressive results. A phase I trial of the combination showed that the 2-year survival rate for all dose cohorts was 79%. At the best-responding dose level (nivolumab 1 mg/kg and ipilimumab 3 mg/kg), the 2-year survival rate was even more impressive—88%. This is compared to a 2-year survival rate of about 15% for patients treated with conventional chemotherapy.
<http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/melanoma>

Clinical Value Evolves Over Time: Ibrutinib


- In November 2013, the FDA granted accelerated approval to ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The approval of ibrutinib was an important milestone for patients with this rare cancer, but continuing research has revealed additional benefits of ibrutinib not recognized at initial approval.



- Source: Boston Healthcare Associates, "The Value of Innovation in Oncology: Recognizing Emerging Benefits Over Time," Boston Healthcare Associates, Inc., May 2015.

Innovations in Cancer Treatment Could Echo HIV/AIDS Successes

- As HIV/AIDS treatments improved, spending became more sustainable.



“We used to think HIV costs would overwhelm us....but we figured it out and let drug development progress... similarly, cancer care will evolve.”

— Ira Klein, M.D.,
M.B.A., FACP, Aetna

“Remember HIV?... thanks to a wave of new discoveries that came both from academic centers and the pharmaceutical industry, the HIV crisis was transformed into a stable condition which is managed very differently by society where good drugs are available. They are controlling the disease, and society has been saving an enormous amount of money as a result of these innovative drugs by providing better care out of hospitals.”

— Hervé Hoppenot, President,
Incyte Pharmaceuticals

- Sources: National Center for Health Statistics. Health, United States, 2014: With Special Feature on Adults Aged 55–64. Hyattsville, MD. 2015. <http://www.cdc.gov/nchs/data/hus/hus14.pdf> page 125 <http://www.cdc.gov/nchs/hus/contents2014.htm#029>; M Kean, T Lessor (Eds.), “Sustaining Progress Against Cancer in an Era of Cost Containment Discussion Paper,” June 2012, available at: www.TurningTheTideAgainstCancer.org.

Lilly & Hanmi Collaboration - Autoimmune Conditions

Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy (March 19,2015).

- Exclusive license and collaboration agreement for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.
- Molecule is ready to enter Phase II and will be investigated for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis, Sjögren's syndrome, and other related conditions.

"Lilly is committed to changing patient expectations in some of the world's most debilitating disease areas, and we're building a portfolio of potential advances in immunology through our own research and key collaborations such as with Hanmi. We're highly encouraged by the potential of HM71224 to deliver an innovative, first-in-class treatment option."


-Thomas Bumol, Ph.D., senior vice president, biotechnology and immunology research at Lilly

"We are very pleased to be collaborating with Lilly on HM71224, and through this agreement and R&D collaborations, we are excited to drive the joint project forward with the ultimate aim to offer new medical treatment options to patients with autoimmune disorders and related conditions."

- Dr. Gwan Sun Lee, CEO/President of Hanmi Pharmaceutical

Hanmi Pharmaceutical is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products. More information on Hanmi is available at www.hanmipharm.com.

Alzheimer's disease: a difficult challenge




A recent report from PhRMA that highlights the challenges of achieving real progress in treating Alzheimer's disease (available from the PhRMA website)

The potential to change the trajectory of Alzheimer's disease

FIGURE 4

Impact of a Treatment That Delays Onset by Five Years on the Number of Americans Age 65 and Older Living with Alzheimer's Disease, 2015-2050




*Totals may not add due to rounding.

Source: A report to the Alzheimer's Association of America, completed by The Lewin Group, Washington DC in 2010. With permission.

The potential to change the trajectory of Alzheimer's disease

FIGURE 6

Impact of a Treatment That Delays Onset by Five Years on Total Costs, 2015-2050



Current trajectory	\$226	\$267	\$340	\$451	\$596	\$767	\$942	\$1,101
Delayed onset	\$226	\$267	\$340	\$368	\$417	\$509	\$622	\$734
Savings	\$0	\$0	\$0	\$83	\$180	\$259	\$320	\$367

*All cost figures are reported in 2015 dollars. Totals may not add due to rounding.

Source: A report to the Alzheimer's Association of America, completed by The Lewin Group, Washington DC in 2010. With permission.

However, not all important innovation is “breakthrough”

- Innovation and progress in oncology has most often come in small steps
- While this has led to important gains in survival in many cancers, the rate of progress is too slow
- That is why Eli Lilly and Company developed its PACE initiative
(Patient Access to Cancer Care Excellence)
- One specific project of PACE has been to develop a tool to illustrate the continuous nature of innovation in cancer and to help identify the gaps and needs

PACE Continuous Innovation Indicators

ecancermedalscience

PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments

Silvia Paddock¹, Lauren Brum¹, Kathleen Sorrow¹, Samuel Thomas¹, Susan Spence¹, Catharina Maulbecker-Armstrong¹, Clifford Goodman¹, Michael Peake¹, Gordon McVie¹, Gary Geipel¹ and Rose Li¹

¹Rose Li and Associates, Inc., Bethesda, Maryland 20817, USA
²Prevention and Health Promotion, State of Hessen, 65187 Wiesbaden, Germany
³Center for Comparative Effectiveness Research, The Lewin Group, Falls Church, Virginia 22042, USA
⁴University of Leicester, LE1 7RH, United Kingdom; National Lung Cancer Audit, Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, London NW1 4LE, United Kingdom; National Cancer Intelligence Network, London SE1 8UG, United Kingdom
⁵European Institute of Oncology, Milan 20146, Italy; University of Milan, Italy; University of Glasgow, G12 8QQ, United Kingdom; University of Wales, Cardiff, South Glam C10 3NS, United Kingdom; Founding Editor of *ecancer.org*
⁶Lilly Oncology, Indianapolis, Indiana 46285, USA

Correspondence to: Silvia Paddock. Email: silvia.paddock@roseliassociates.com

Abstract

Concerns about rising health care costs and the often incremental nature of improvements in health outcomes continue to fuel intense debates about 'progress' and 'value' in cancer research. In times of tightening fiscal constraints, it is increasingly important for patients and their representatives to define what constitutes 'value' to them. It is clear that diverse stakeholders have different priorities. Harmonisation of values may be neither possible nor desirable. Stakeholders lack tools to visualise or otherwise express these differences and to track progress in cancer treatments based on variable sets of values.

The Patient Access to Cancer care Excellence (PACE) Continuous Innovation Indicators are novel, scientifically rigorous progress trackers that employ a three-step process to quantify progress in cancer treatments: 1) mine the literature to determine the strength of the evidence supporting each treatment; 2) allow users to weight the analysis according to their priorities and values; and 3) calculate Evidence Scores (E-Scores), a novel measure to track progress, based on the strength of the evidence weighted by the assigned value.

We herein introduce a novel, flexible value model, show how the values from the model can be used to weight the evidence from the scientific literature to obtain E-Scores, and illustrate how assigning different values to new treatments influences the E-Scores.

Published: 07/01/2015

Received: 14/11/2014

ecancer 2015, 9:948 DOI: 10.3332/ecancer.2015.948

Copyright: © the authors; licensee ecancermedalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Policy

PACE Continuous Innovation Indicators - Supplemental Information

Appendix 3: Sources of variability, strategies to maximize consistency, and estimates of nonconsistency scores.

Goal	Specific Task	Source of Possible Variability	Strategies to Maximize Consistency	Records Reporting Nonconsistency
1	Identify relevant literature for each disease	Analysis of search differences between reviewers	Standardized criteria for inclusion/exclusion of articles from published sources. Consistent reporting of search terms used for each disease	0/26
2	Identify relevant literature for each disease	Interpretation of abstracts	Standardized criteria for inclusion/exclusion of articles from published sources. Consistent reporting of search terms used for each disease	0/26
3	Calculate evidence scores	Interpretation of abstracts	Standardized criteria for inclusion/exclusion of articles from published sources. Consistent reporting of search terms used for each disease	0/26
4	Calculate evidence scores	Interpretation of abstracts	Standardized criteria for inclusion/exclusion of articles from published sources. Consistent reporting of search terms used for each disease	0/26
5	Calculate evidence scores	Interpretation of abstracts	Standardized criteria for inclusion/exclusion of articles from published sources. Consistent reporting of search terms used for each disease	0/26
6	Calculate evidence scores	Interpretation of abstracts	Standardized criteria for inclusion/exclusion of articles from published sources. Consistent reporting of search terms used for each disease	0/26

Paddock et al. 7

PACE Continuous Innovation Indicators - Supplemental Information

Appendix 3: Procedures for assigning piece of evidence to calculate E-Scores.

Goal: To determine which Pieces of Evidence should increment the E-Score.

Introduction: The evidence that a particular treatment improves overall survival is complex, changing, it is critical to assess the effectiveness of treatment in light of underlying biology. The Continuous Innovation Indicators are designed to help clinicians and patients understand the evidence for a particular treatment. The Continuous Innovation Indicators are designed to help clinicians and patients understand the evidence for a particular treatment. The Continuous Innovation Indicators are designed to help clinicians and patients understand the evidence for a particular treatment.

When setting a piece of evidence as a Piece of Evidence for a treatment in a given disease, it is critical to assess the effectiveness of treatment in light of underlying biology. The Continuous Innovation Indicators are designed to help clinicians and patients understand the evidence for a particular treatment. The Continuous Innovation Indicators are designed to help clinicians and patients understand the evidence for a particular treatment.

Procedure for setting the piece of evidence as a Piece of Evidence for a treatment in a given disease:

- If the piece of evidence is a randomized controlled trial (RCT) that compares the treatment to a control, it is a Piece of Evidence for the treatment.
- If the piece of evidence is a non-randomized study, it is a Piece of Evidence for the treatment only if it is a high-quality study.
- If the piece of evidence is a case report or series, it is a Piece of Evidence for the treatment only if it is a high-quality study.
- If the piece of evidence is a case report or series, it is a Piece of Evidence for the treatment only if it is a high-quality study.

Paddock et al. 8

PACE Continuous Innovation Indicators - Supplemental Information

Appendix 3: Detailed explanation of Value Matrix square assignments.

Area	Type of Study/Treatment	Current Score for a disease-treatment pair	Assigned Score for a disease-treatment pair
A	Randomized controlled trial (RCT)	1	1
B	Non-randomized study	0	0
C	Case report or series	0	0
D	Expert opinion	0	0
E	Expert opinion	0	0
F	Expert opinion	0	0
G	Expert opinion	0	0
H	Expert opinion	0	0
I	Expert opinion	0	0
J	Expert opinion	0	0

Paddock et al. 9

PACE Continuous Innovation Indicators - Supplemental Information

Appendix 4: Procedure for determining circle size of treatments on the Value Matrix.

Goal: To graphically depict the prominence of the use of various cancer treatments with a given disease of the Value Matrix.

Method: Each treatment in the Evidence Indicators database is represented as a circle in the Value Matrix. The size of the circle depicts the relative prominence of the use of the treatment for the disease. The size of the circle is determined by the number of articles in the Evidence Indicators database that support the use of the treatment for the disease. The size of the circle is determined by the number of articles in the Evidence Indicators database that support the use of the treatment for the disease.

Circle size assignments:

- Circle size assigned to represent 1-10 articles.
- Circle size assigned to represent 11-20 articles.
- Circle size assigned to represent 21-30 articles.
- Circle size assigned to represent 31-40 articles.
- Circle size assigned to represent 41-50 articles.
- Circle size assigned to represent 51-60 articles.
- Circle size assigned to represent 61-70 articles.
- Circle size assigned to represent 71-80 articles.
- Circle size assigned to represent 81-90 articles.
- Circle size assigned to represent 91-100 articles.

Paddock et al. 10

PACE Continuous Innovation Indicators - Supplemental Information

Appendix 5: Value matrix: The effect of value weights on E-Scores.

The figure shows a value matrix with diseases on the x-axis and treatments on the y-axis. The cells contain E-Scores. The matrix is color-coded by E-Score range: 0-10 (yellow), 11-20 (orange), 21-30 (red), 31-40 (dark red), 41-50 (purple), 51-60 (blue), 61-70 (green), 71-80 (light green), 81-90 (light blue), 91-100 (dark blue).

Paddock et al. 11

PACE Continuous Innovation Indicators - Supplemental Information

Appendix 6: Two examples of ways in which the indicators can support policy decisions.

Policy Decision 1 - Treatment:

Many clinicians and organizations have expressed frustration with the "incremental" advances in cancer research of the past 10 years. For the first time, we have developed a tool to understand the strength of the "incremental" data and to identify treatments that may sustain them.

The PACE Continuous Innovation Indicators Value Matrix helps users to evaluate their treatment may be sustained. It is a tool to help clinicians and organizations to understand the strength of the "incremental" data and to identify treatments that may sustain them.

Policy Decision 2 - Research:


The current literature on cancer research is heavily biased towards the study of the "incremental" data. The PACE Continuous Innovation Indicators Value Matrix helps users to understand the strength of the "incremental" data and to identify treatments that may sustain them.

The current literature on cancer research is heavily biased towards the study of the "incremental" data. The PACE Continuous Innovation Indicators Value Matrix helps users to understand the strength of the "incremental" data and to identify treatments that may sustain them.

Paddock et al. 12


Paddock et al. *ecancermedalscience* Jan. 2015
 Policy paper; details on methodology provided in the supplemental information

PACE Innovation Indicators – Method



Database Name	Data Type	Number of Records	Comment
PubMed	Phase 2/3 clinical trial results in PubMed	4015	All records for 12 cancers of interest that mention “overall survival”
Oncology Reference (DeVita 9 th Edition)	All PubMed references exported electronically	3325	Includes meta-analyses, register studies, etc. not covered in dataset above
Cochrane Library Database	Evidence Reviews	457	Only publicly accessible information is included
National Cancer Institute Physician Data Query (PDQ)	PubMed References quoted in the Health Professional Treatment Summaries	1549	We included all PDQ references, not only those associated with evidence ratings
PubMed and Books	Historic records	~25	Some innovation predates the above sources and has to be extracted from historical papers manually.
Citeline Pharmaprojects	Approval/Launch Data	120	Each of these compounds may be used in multiple cancers; the total number of data points is 524
Total		9491	

Scientific Value



Color codes:

Surgery

Radiotherapy

Chemotherapy

Treatment class evidence

Other (e.g., palliative care)

Testicular Cancer – PACE Value Matrix


Surgery →

Radiotherapy →


Chemotherapy

Combination

Therapies →



Evidence (E)-Scores as a new measure of progress



Platform Overview




PACE Continuous Innovation Indicators

Compare Instructions Values About us


Select Set: Breast Cancer for Plot 1

Save picture




Select Set: Testicular Cancer for Plot 2

Save picture




Select Set: Pancreatic Cancer for Plot 3

Save picture




Select Set: Melanoma for Plot 4

Save picture




Compare Results

Save picture




Testicular Cancer – Today





Progress Tracker



01/01/2015



Results by Treatment Type



Getting the policy settings right

- An ecosystem that supports pharmaceutical innovation needs to ensure:
 - availability of excellent human resources,
 - access to government investment, private and venture capital,
 - protection of intellectual property rights,
 - predictable and transparent government policies.
- In addition, tomorrow's innovation requires additional conditions such as:
 - drug pricing policies that recognize and reward innovation, including the continuous nature of innovation in oncology,
 - overall regulatory, HTA and pricing processes that ensure patients' rapid accessibility to treatments.
 - increased investment in health system data that can support risk-sharing and related reimbursement agreements

Conclusions

- The innovation pipelines of the bio-pharmaceutical industry are delivering some exciting advances.
- Many of these have the potential to transform health outcomes (survival, functional ability and quality of life) in ways that change the experience of acute treatment. More patients may live longer with chronic, manageable illnesses and / or avoid progression to more severe illness.
- However, not all innovation is “breakthrough” and regulatory, HTA and reimbursement policies need to recognize this.